Regenxbio (RGNX) Q2 2024 earnings summary

Executive summary

• Lead gene therapy programs, including RGX-202 (Duchenne), RGX-314 (wet AMD, DR, DME), and RGX-121 (MPS II), advanced toward pivotal trials and commercialization, supported by positive clinical data and regulatory progress.

• RGX-202 showed robust microdystrophin expression and favorable safety in Phase II, with pivotal trial design to be shared late Q3/early Q4 2024.

• Accelerated regulatory timelines for RGX-314 in diabetic retinopathy, with pivotal trial initiation expected in 1H 2025 and a $200M milestone payment anticipated upon first patient dosing.

• RGX-121 pivotal trial met its primary endpoint; rolling BLA submission planned for Q3 2024, with potential for a priority review voucher in 2025.

• The company licenses its NAV Technology, generating revenue from Zolgensma royalties and milestone payments, and completed a $131.1M public offering to strengthen its cash position.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $327.3M as of June 30, 2024, up from $314.1M at year-end 2023, mainly due to a $131.1M public offering.

• Revenues for Q2 2024 were $22.3M, up from $20.0M in Q2 2023, driven by higher Zolgensma royalties.

• Net loss for Q2 2024 was $53.0M ($1.05 per share), improved from $72.1M ($1.66 per share) in Q2 2023.

• R&D expenses decreased to $48.9M in Q2 2024 from $59.9M in Q2 2023, reflecting lower manufacturing and personnel costs.

• G&A expenses fell to $18.9M from $23.7M year-over-year.

Outlook and guidance

• Cash runway expected to fund operations into 2026, excluding potential milestone and voucher monetization.

• Pivotal trial for RGX-202 in Duchenne planned for Q4 2024; pivotal trial for RGX-314 in DR expected to start in 1H 2025.

• Rolling BLA for RGX-121 to begin in Q3 2024; approval could yield a priority review voucher.

• Management expects continued operating losses and significant R&D spending as product candidates advance.